The CD34 antigen is expressed by committed and uncommitted hematopoietic progenitor cells and is increasingly used to assess stem cell content of peripheral blood progenitor cell (PBPC) collections. Quantitative CD34 expression in PBPC collections has been suggested to correlate with engraftment kinetics of PBPCs infused after myeloablative therapy. We analyzed the engraftment kinetics as a function of CD34 content in 692 patients treated with high-dose chemotherapy (HDC). Patients had PBPCs collected after cyclophosphamide based mobilization chemotherapy with or without recombinant human granulocyte colony-stimulating factor (rhG-CSF) until r2.5 x 10' CD34' cells/kg were harvested. Measurement of the CD34 content of PBPC collections was performed daily by a central reference laboratory using a single technique of CD34 analysis. Forty-five patients required a second mobilization procedure to achieve r2.5
x 10' CD34+ cells/kg and 15 patients with less than 2.5 X 10' CD34+ cells/kg available for infusion received HDC. A median of 9.94 x 1 0 ' CD34+ cells/kg (range, 0.5 to 112.6 x 1 0 ' CD34+ cellslkg) contained in the PBPC collections was subsequently infused into patients after the administration of HDC. Engraftment was rapid with patients requiring a EMATOPOIETIC RECOVERY after the administration of myeloablative therapy and infusion of autologous bone marrow (ABM) is relatively prolonged and associated with considerable morbidity.'" Administration of myeloid growth factors improves the time to neutrophil recovery, but has no beneficial effect on platelet recovery."6 Autologous peripheral blood progenitor cells (PBPCs) have increasingly been used for hematopoietic recovery after the administration of high-dose chemotherapy (HDC) with or without total body irradiation (TBI) for patients with malignant diseases. Several studies suggest that autologous PBPCs alone are superior to ABM with regard to the rate of hematopoietic recovery achieved after the administration of myeloablative thera~y.7.~ Administration of myelosuppressive chemotherapy, recombinant human hematopoietic growth factors, or chemotherapy with growth factors in combination have all been shown to increase circulating blood progenitor cells.1°"6 Despite a growing acceptance of the advantage of mobilized PBPCs, there is no universally accepted approach to measure blood progenitor cells and there is no agreement on the optimal or minimal number of progenitor cells that should be infused after the administration of myeloablative therapy. Centers performing PBPC collections have attempted to predict blood progenitor cell content by measuring the mononuclear cell (MNC), total nucleated cell (TNC), colony-forming unit (CFU), and the CD34 antigen content of PBPC collection^.^^^"^^ Measurement of the CD34 antigen in PBPC collections may be the most powerful and pragmatic method for reliably predicting engraftment kinetics of PBPCs infused after myeloablative the rap^.^"' To evaluate the relationship between CD34+ cell content and engraftment kinetics of PBPCs, we have analyzed the relationship between patient and treatment characteristics, including the CD34 content of PBPCs, and engraftment kinetics in 692 patients receiving PBPCs after myeloablative HDC.
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Blood, Vol86, No 10 (November 15), 1995: pp 3961-3969 median of 9 days (range, 5 to 38 days) to achieve a neutrophil count of 0.5 x 10s/L and a median of 9 days (range, 4 to 53+ days) to achieve a platelet count of a20 x 1@/L. A clear dose-response relationship was evident between the number of CD34' cells per kilogram infused and neutrophil and platelet engraftment kinetics. Factors potentially influencing the engraftment kinetics of neutrophil and platelet recovery were examined using a Cox regression model. The single most powerful mediator of both platelet ( P = .OOOl) and neutrophil (P = .0001) recovery was the CD34 content of the PBPC product. Administration of a post-PBPC infusion myeloid growth factor was also highly correlated with neutrophil recovery (P = .OOOl). Patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin had more rapid platelet recovery than patients receiving other regimens (P = .006), and patients requiring 2 mobilization procedures versus 1 mobilization procedure to achieve r2.5 x 1 0 ' CD34+ cells/kg experienced slower platelet recovery ( P = .005). Although a minimal threshold CD34 dose could not be defined, 25.0 x 1 0 ' CD34+ cellslkg appears to be optimal for ensuring rapid neutrophil and platelet recovery.
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MATERIALS AND METHODS

Patient Selection
Between January 1990 and October 1994, 703 patients were entered on protocols administering high-dose chemotherapy supported by PBPCs alone. Patients were eligible for study if they had relapsed Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), stage I1 or ID breast cancer with more than 8 axillary lymph nodes involved with tumor, stage TV breast cancer, ovarian cancer, relapsed sarcoma, or multiple myeloma. Additional inclusion criteria included being between 18 and 65 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and evidence of adequate hepatic, renal, and cardiac function. All patients signed an informed consent form approved by the institutional review board of the hospital where the therapy was administered.
Mobilization of PBPCs
Patients may have been enrolled on various pmtocols evaluating mobilization of PBPCs. Seventy patients receiving cyclophosphamide (Cy) alone (n = 27), cyclophosphamide plus etoposide (CE) alone (n = 19), or CE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF n = 24) have been reported previously. '6 Between July 1991 and April 1995 Based on a previous analysis, we recommended collection of a target level of 2.5 X IO6 CD34+ cellskg before proceeding to HDC.' Therefore, 45 of 692 patients required a second course of mobilization therapy that was accomplished with chemotherapy alone (n = 28), chemotherapy and rhG-CSF (n = 15), or rhG-CSF alone (n = Six hundred and forty-six patients received 6 pgikgld rhG-CSF (Amgen, Thousand Oaks, CA) administered subcutaneously from the day after the end of mobilization until completion of leukapheresis. All patients underwent analysis of PBPCs concurrent with leukapheresis.
2).
Collection and Cryopreservation of PBPCs
After the administration of chemotherapy, patients had complete blood counts measured daily and began leukapheresis when the total white blood count recovered to 1,000/pL. Leukapheresis was performed daily with a Fenwal CS-3000 Plus (Baxter, Deerfield, IL) for 3-to 4-hour sessions processing 10 L of whole blood per session until analysis of the product confirmed collection of greater than 2.5 X lo6 CD 34+ celldkg patient weight. The final product containing 10% dimethyl sulfoxide (DMSO) in autologous platelet-deficient plasma was frozen in a liquid nitrogen-dependent Gordinier controlled rate freezer (Gordinier Electronics, Roseville, MI) and was maintained in the vapor phase of liquid nitrogen less than -130°C.
Measurement of Progenitor Cell Content
A I-mL sample of each PBPC product was removed, diluted with 7.5 mL of RPMI-1640 containing 10% heat-inactivated fetal bovine serum in an ACD-A vacutainer (Becton Dickinson, San Jose, CA). Samples were placed in Styrofoam mailers, insulated from the ice pack, and shipped via overnight carrier to the central laboratory. The routine analysis of these products included a total nucleated cell count, lymphocyte percentage, CD34' cell enumeration, and measurement of the colony-forming unit-granulocyte-macrophage (CFU-GM) content. The CFU-GM analyses were performed by a single laboratory using conditions and endpoints previously described.' This measurement was discontinued after the first 355 samples were found to be highly correlated ( r = .72) with the CD34' cell content.27 Analysis of CD34 antigen content was performed in the central laboratory using a single technique, as described below.
Equipment. The Coulter (EPICS Profile 11; Coulter, Hialeah, FL) flow cytometer was used in the described analyses. The equipment is routinely calibrated and verified for stability and output. Daily quality controls include the check of optical alignment and instmment stability (DNA Check Beads; Coulter), color compensation (DuoComp Beads; FCSC, Research Triangle, NC), and log amplifier linearity (Immunobrite Kit; Coulter).
Procedural and reagent quality control. CytoTrol cells (Coulter) and the CD34+ acute myelogenous leukemia KG-1 cell line (ATTC-CCL246) were stained in parallel with the PBPC samples. These cells must fall within a predetermined range of normal values for each marker. Isotypically matched irrelevant murine monoclonal antibodies were used to determine nonspecific binding of each sample analyzed.
Staining samples. A total of I X 10' cells was stained for each of the three tubes being analyzed (1) Simultest Leukogate (CD45-FITC/CD14-PE), (2) Simultest Negative control (MuIgG,-FITC/ MuIgG,,-PE), and (3) HPCA-2 (CD34-FITC; all from Becton Dickinson Immunocytometry Systems, Mountain View, CA). Twenty microliters of the appropriate antibody reagent was added to the sample and allowed to incubate in the dark at room temperature for 15 minutes. Twenty-five microliters of heat-inactivated fetal calf serum were added to each tube before red blood cell lysis with Immunoprep Lysing reagents on the Multi-Q-prep (Coulter). AH samples and controls were washed with 3 mL phosphate-buffered saline and resuspended in 200 pL of 1 % paraformaldehyde for immediate analysis.
Procedure. The Leukogate sample was used to define the lymphocyte gate drawn from light scatter characteristics to include a maximum CD45+/CD14-cells in the lymphocyte region. The ranges acceptable for analysis were set at 52.0% CD45+/CD14+ and >95% CD45' (Fig IA) . A second gate was drawn to include all white blood cells while eliminating dead cells and debris.
The analysis region defining positive events within the lymphocyte gate was set using the Simultest negative control tube, in which the FITC-positive region routinely included 10.2% of the events ( Fig  IB) . Subsequent to setting the above parameters, the tube containing CD34-stained cells was analyzed and the percentage in the FITCpositive region of the Simultest-negative control was subtracted from the CD34' percentage to obtain the reported percentage positive. Based on these results, the absolute number of CD34' cells in each product was calculated as follows: lymphocyte % = (events in gate no. I)/(events in gate no. 2) (CD34 tube used); (CD34' %/loo) X (lymphocyte %/loo) X (total no. of nucleated cells in harvested product) = absolute no. of CD34' events.
Treatment Regimens
Ninety-five patients with NHL and 20 patients with HD were treated with 300 mg/m'/intravenously (IV) carmustine on day -7, 150 mg/mZ/IV etoposide every 12 hours on days -6 to -3, 100 mg/ m'/IV cytosine arabinoside every 12 hours on days -6 to -3, and 35 mgkg/IV/d cyclophosphamide on days -6 to -3 (BEAC).'" Three hundred eight patients with metastatic breast cancer, 173 patients with high-risk stage I1 or I11 breast cancer, and 35 patients with ovarian cancer were treated with high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb). Patients received 167 mg/m' thiotepa, 2 g/m' cyclophosphamide, and 267 m g h ' carboplatin in equal bolus doses on days -5 , -4, and -3. Ten patients with multiple myeloma and 5 patients with low-grade NHL were treated with busulfan at 1.0 mg/kg/orally (PO) every 6 hours on days -7 through -4 and cyclophosphamide at 75 mgkg/IV/d on days -3 and -2 (BuCy). Twenty-nine patients received 12 mgkg busulfan, 100 mgl m' melphalan, and 500 mg/m2 thiotepa (BuMelT), as previously described." Seventeen patients were treated with ifosphamide (10 g/mz) at 2.5 g/m' as a 24-hour continuous infusion on days -6 through -3, etoposide (1,400 mg/rn') at 350 mg/m*/dlIV Over 3 hours, and carboplatin (1, 200 mgh') at 300 mg/m2/d/lv Over 2 hours on days -6 to -3 (ICE). Cryopreserved PBPCs were thawed and infused 24 to 48 hours after the last dose of chemotherapy, as previously described.' The day of PBPC infusion was designated day 0 in all treatment regimens.
Supportive Care
Patients analyzed for this report were treated in 28 US medical centers under the care of 159 community medical oncologists. TWO For personal use only. on October 27, 2017. by guest www.bloodjournal.org From 
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centers were in operation 12 months or less, 10 centers had been operational for 13 to 24 months, 7 centers were in operation for 25 to 36 months, and 9 centers had been operational for greater than 36 months. Outpatient care was delivered through specialty centers committed to administering HDC. Outpatient support staff of each center underwent identical primary training and continuing education and followed standardized protocols, standing orders, and supportive care guidelines. All participating physicians were experienced in the induction therapy of acute myelogenous leukemia or had undergone formal training in bone marrow transplantation (BMT).
Patients received mobilization chemotherapy and HDC in an outpatient treatment facility with daily surveillance for complications warranting hospital admission such as febrile neutropenia or inadequate oral intake. Patients who were serologically positive for herpes simplex virus received prophylactic acyclovir. Patients received prophylactic tobramycin, ceftriaxone, and vancomycin when appropriate during neutropenia. Indwelling catheters were instilled with a solution containing 5,000 U/mL heparin and 25 pg/mL vancomycin, with the solution aspirated and discarded at each change. Red blood cell and platelet transfusions were administered empirically for a hemoglobin level less than 8.5 mg/dL and a platelet count 5 2 0 X 109/L, respectively. All blood products were irradiated to 2,500 cGy before their administration.
Before March 1991, patients did not receive a post-PBPC infusion myeloid growth factor (n = 40). After March 1991, patients may have received 250 pg/mZIIV/d recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF n = 27), 5 pg/kg/ subcutaneous (SC)/d rhGM-CSF (n = 29), or 6 pgikg/SC/d rhG-CSF (n = 548) as standard treatment. In 1992,48 patients were part of a randomized study comparing 6 pgkg/SC/d rhG-CSF (n = 35) versus no growth factor (n = 13) and have been previously rep~rted.~" All growth factors were administered after PBPC infusion until the absolute neutrophil count (ANC) was greater than 0.5 X lo9 for 3 days.
Statistical Analysis
All data were collected using a custom designed distributed data system, reviewed at a central clinical trials center, and analyzed using the SAS system (SAS institute, Cary, NC). Neutrophil engraftment was defined as the first of 2 consecutive days on which the patient's ANC exceeded 0.5 x 109/L after the nadir. Platelet transfusion independence was defined as the first of 7 consecutive days on which an individual patient's platelet count exceeded 20.0 X 109L unsupported by transfusions. Univariate associations between prognostic factors and hematopoietic recovery were evaluated using a log-rank test (log rank) and plotted according to the method of Kaplan and Meier." Patients who died before engraftment of either lineage were censored on the date of death and are designated by a plus sign. Multivariate associations were assessed using the Cox proportional hazards regression modeL3'
RESULTS
Patient Characteristics
Patient-and treatment-related characteristics of 692 evaluable patients are displayed in Tables 1 and 2 , respectively. Eleven of the 703 original patients were not considered to be evaluable. Seven patients were missing 2 1 CD34 samples; therefore, the exact total number of infused CD34+ cells was unknown. Four patients died from complications of therapy within 4 days of PBPC infusion and were therefore not considered eligible for engraftment.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From A multivariate analysis of factors predictive of neutrophil recovery was performed using a step-wise selection algorithm. Cox proportional hazards models using CD34+ cells per kilogram as either a quadratic or linear variable or the log of CD34+ cells per kilogram were analyzed. Because the log CD34 gave the best overall fit and was not statistically significant from the other models, log CD34 was entered into the multivariate analysis. Other variables included in the model were 1 versus 2 cycles of mobilization, rhG-CSF use during either mobilization (yes v no) or post-PBPC infusion (rhG-CSF v rhGM-CSF v none), age ( 4 0 v >50 years), number of prior chemotherapy regimens (0 or 1 v 2 or more), prior radiotherapy (yes v no), and binary (yes v no) variables representing regimen. For the purposes of this analysis, a single variable was used with a value of yes if the patient received either of the busulfan (BuCy or BuMelT) containing regimens.
The variables showing significance for neutrophil recovery in the Cox model were the use of a myeloid growth factor post-PBPC infusion (x2 = 67.45, P = .0001) and the log of CD34 dose (x2 = 43.08, P = .OOOl). In a separate analysis, binary variables were used for each of the levels of CD34 dose shown in Table 3 . Using a categorical value, three dose levels for CD34 count were significant: less than 7.5, 7.5 to 10, and greater than 10 X IO' CD34' cellskg (P < .0001). If the CD34 dose was greater than 7.5 X 106/kg, there was a 95% probability of having neutrophil recovery by day 13 (Table 4 ). The Kaplan-Meier curves for CD34 dose are illustrated in Fig 2. 
Platelets
The median time to achieve a platelet count greater than 20 x lo9& was 9 days (range, 4 to 53+ days A total of 684 of 692 patients had documented engraftment of neutrophils and platelets. Eight patients died before achieving neutrophil or platelet engraftment. Three patients died before achieving an ANC 20.5 X lo'& on days +5, +lo, and + l 5 of progressive disease, idiopathic pneumonia syndrome (IPS),33 and gastrointestinal hemorrhage, respectively. Six patients died before achieving platelet transfusion independence. Four patients died between days +8 and + 13 of sepsis, 1 on day + 15 from gastrointestinal hemorrhage, and 1 on day +53 of IPS.
PBPCs
The infused products for the 692 patients were characterized by the numbers of total nucleated cells per kilogram and CD34+ cells per kilogram. The Cm-GM assay was also performed in 286 patients. The medians and ranges for the total number of cells per kilograms were as follows: total nucleated cells, 4.8 X 1O8kg (0.4 to 39.5 X 108/kg); total CD34+ cells, 9.94 X 106/kg (0.5 to 112.6 X 108/kg); and total CFU, 30.8 X 104/kg (1.3 to 499.1 X 104kg). More details of CD34 counts are given in Table 2 .
Hematopoietic Engraftment
Patients required a median of 9 days (range, 5 to 38 days) to achieve an ANC greater than 0.5 X 109/L. Table 3 lists the median time and range of neutrophil and platelet recovery according to various characteristics. Significant associations were observed in univariate analysis according to CD34 dose, the use of rhG-CSF during mobilization, the use of a post-PBPC infusion myeloid growth factor, 2 mobilization Abbreviation: +, patient death on day +53 without platelet recovery.
* P < .05 using a log rank test for overall difference between the t P < .05 using a log rank test between patients receiving regimen groups.
compared with all other patients.
and multivariate analyses were performed using the same variables and technique described for neutrophils. In the univariate analysis, factors significantly predicting platelet recovery included CD34 dose, the use of growth factors during mobilization, the number of prior chemotherapy regimens, and the number of mobilization procedures performed. Patients receiving CTCb recovered platelets significantly faster when compared with all other patients, and patients receiving BEAC were significantly slower. However, in the Cox Absolute neutrophil recovery is defined as the time to achieve an ANC of 0.5 x 10s/L for 2 consecutive days. model, the only variables to achieve statistical significance were the log of the CD34 dose (x2 = 37.0, P = .OOOl), patients receiving CTCb (x2 = 7.4, P = .006), and patients requiring 2 mobilization procedures versus 1 mobilization procedure to achieve 22.5 X lo6 CD34+ cellskg (x2 = 8.02, P = .005). Using a categorical variable, three dose levels for CD34 count were significant: less than 5.0 X lo6, 5.0 to 10 X lo6, and greater than 10X106 CD34+ cellskg (P < .OOOl). If a value 2 5 . 0 X lo6 CD34' cellskg was infused, there was a 95% probability of platelet engraftment by day 20 ( Table 5 ). The Kaplan-Meier plots corresponding to these three dose levels are shown in Fig 3. 
DISCUSSION
Infusion of PBPCs after myeloablative therapy has been shown to achieve rapid and sustained long-term hematopoietic reconstitution of neutrophils and platelet^.'.^ Measurement of the stem cell content of PBPC collections is desirable to time leukapheresis, to maximize the efficiency of PBPC collections, and to collect the optimal number of stem cells to ensure rapid and sustained hematologic recovery. The ideal method of measuring stem cells should be rapid, inexpensive, and possess clinically relevant predictive value on engraftment kinetics. The present study found that the CD34 content of the PBPC product and administration of a post-PBPC infusion myeloid growth factor were the most important factors influencing the time to neutrophil recovery after the administration of myeloablative chemotherapy. The time to platelet transfusion independence was influenced by the CD34 content of the PBPC product, the HDC regimen CTCb, and the number of mobilization procedures required to achieve 22.5 X lo6 CD34' cellskg. This and other analyses confirm the observation that administration of a myeloid growth factor after PBPC infusion improves the rate of neutrophil but not platelet r e~o v e r y . '~.~~ More interestingly, these data suggest that a clear dose-response relationship exists between the quantity of infused CD34+ cells and the kinetics of both neutrophil and platelet recovery. This relationship can be exploited to predict short-term hematopoietic recovery with reasonable certainty.
Investigators have previously attempted to measure the stem cell content of PBPC collections to predict subsequent engraftment kinetics. A variety of surrogates, including the TNC and MNC c o~n t , '~.~~.~' CFU-GM,'9-24 and CD34 content, have been e v a l~a t e d .~~~~~* '~~~-~~ I n general, a simple measurement of the TNC and MNC counts is not an ideal surrogate for predicting engraftment kinetics because of the wide range in hematopoietic progenitor cell frequency relative to other cells. These measurements have been reported to have a poor correlation with engraftment kinetics,18.20.2' and a correlation between the TNC content and engraftment kinetics was not observed in our analysis.
Functional assays of stem cell activity that rely on in vitro growth of colonies have also been evaluated for correlation with engraftment kinetics. These include the CFU-GM, burst-forming unit-erythroid (BFU-E), and the long-term marrow culture (LTMC)
The LTMC assay more accurately measures primitive progenitors but is timeconsuming, cumbersome, semiquantitative, and therefore not ideal for clinical use. The CFU-GM has been widely used by several investigators to define threshold values that predicted hematologic recovery. Most investigators have reported a good Correlation between CFU-GM and neutrophil recovery, but not all have shown a strong correlation between the C m -G M and platelet r e c o~e r y .~~'~~~~.~~ This is not surprising because the CFU-GM is believed to measure more committed myeloid progenitor cell activity. Colony assay measurement is laboratory-dependent, making comparisons between laboratories difficult. Additionally, the C m -G M assay requires 10 to 14 days for interpretation and therefore cannot be used for determining the timing or adequacy of an apheresis product. We previously reported a high correlation between the CD34 and CFU-GM content of PBPC collection~?~' which has been confirmed by ~everal,~~,?'~ but not all, investigators." Because of the high correlation between CD34+ cells and CFU-GM in PBPC collections and the relationship identified between CD34' cell content of the PBPC collection and neutrophil and platelet recovery, we began using CD34 analysis exclusively to determine the adequacy of PBPC collections in 1992.*'
The relationship between CD34 content and neutrophil recovery is nonlinear, and serial threshold values for neutrophil recovery can be defined above which prompt engraftment occurs with increasing confidence. Ninety-five percent of patients receiving greater than 2.5 X IOh CD34' cellskg experience prompt and durable neutrophil recovery by day 18. This can be incrementally improved when increasing numbers of CD34' cells per kilogram are infused. Other investigators evaluating smaller numbers of patients have suggested that a minimum number of CD34+ cells are necessary to achieve rapid hematologic recovery from HDC and PBPC infusion. '8,21,22 Defining an absolute minimal number of CD34' cells necessary for neutrophil engraftment was not possible in this analysis because few patients received less than 2.5 X lo6 CD34' cellskg and all of them experienced neutrophil recovery. Bensinger et all8 were also unable to define a minimum number of CD34' cells per kilogram because both patients in their analysis receiving less than 1.0 X lo6 CD34' cellskg achieved neutrophil and platelet recovery within 28 days. However, they concluded that 1.0 X lo6 CD34' cellskg may be an appropriate threshold value." Our data suggest that a majority of patients receiving greater than 2.5 X lo6 CD34+ cellskg experience rapid neutrophil recovery after myeloablative therapy. An optimal number of infused CD34' cells may be greater as evidenced by a 95% probability of neutrophil recovery at 15 and 13 days in patients receiving 25.0 or 7.5 X lo6 CD34+ cells/ kg, respectively. Additional data at lower CD34 values are necessary to define a true minimum threshold value for CD34' cells and neutrophil engraftment after myeloablative therapy.
Threshold values regarding number of CD34+ cells per kilogram may be more useful for defining platelet recovery than neutrophil recovery after the administration of myeloablative therapy. The present study (evaluating 692 patients) found that the most significant variable influencing platelet engraftment kinetics was the CD34 content of the infused PBPCs. Patients receiving greater than 5.0 X lo6 CD34+ cellskg had a 95% probability of achieving platelet transfusion independence in 20 days. Bensinger et all8 recently reported that patients receiving greater than 5.0 X lo6
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From CD34+ cellskg experienced more rapid platelet recovery after receiving myeloablative therapy than did patients receiving less than 5.0 X lo6 CD34+ cellskg. Other studies have reported a correlation between CD34 content of PBPCs and platelet recovery but have generally not included large numbers of patients and differing methods of PBPC mobilization were This analysis suggests that CD34 enumeration may be a useful surrogate for predicting platelet recovery and that using platelet recovery may be a more appropriate endpoint for determining a threshold CD34 value.
In univariate analyses, we found that pretreatment characteristics, including the amount of prior chemotherapy received, mobilization therapy consisting of chemotherapy plus a growth factor versus chemotherapy alone, and the number of mobilization procedures required to achieve 22.5 X 10" CD34+ cellskg, appeared to significantly effect the rate of neutrophil or platelet recovery. However, in multivariate analyses, this effect was lost and only the number of CD34+ cells infused significantly effected both the rate of neutrophil and platelet recovery. Other patient characteristics, including disease types, the amount of prior chemotherapy, prior radiotherapy, gender, performance status at transplantation, and age, were found not to influence the engraftment kinetics of blood-derived stem cells in patients receiving myeloablative therapy. Mobilization chemotherapy followed by a myeloid growth factor has been previously reported to be superior to chemotherapy alone for mobilizing PBPCs.16 The amount of prior chemotherapy, increasing age, prior radiation, and a history of tumor involvement of marrow have been reported to have an adverse effect on CD34 mobilization.18.2' Taken together, these data suggest that patient or prior treatment characteristics may effect the number of CD34+ cells mobilized, as opposed to the engraftment kinetics of the infused CD34' cells. In fact, our data suggest that many factors previously reported to affect neutrophil and platelet engraftment kinetics may actually be surrogate markers for low CD34+ cell yields. Any analysis evaluating engraftment kinetics may need to be controlled for the progenitor cell content (number of CD34+ cells) infused after myeloablative therapy. Interestingly, patients requiring two attempts to achieve 22.5 X lo6 CD34' cellskg experienced slower platelet recovery than those achieving 22.5 X IO" in a single procedure. The reasons why patients requiring 2 mobilization procedures versus 1 mobilization procedure experience slower platelet recovery is unclear, because these patients were few in number and all had low CD34' cell values infused. Additional data are necessary to confirm this observation. It may be that these CD34+ cells are qualitatively different or that the marrow microenvironment may have greater damage because difficult to mobilize patients were more heavily pretreated and prior chemotherapy exposure is known to negatively influence PBPC mobilization.
Treatment-related characteristics, including the type of preparative regimen and administration of a post-PBPC infusion myeloid growth factor, have also been reported to influence engraftment kineti~s.l*.'~.'~ TBI-and busulfan-containing preparative regimens have been reported to be associated with slower neutrophil recovery by some investig a t o r~~~*~~ and more rapid neutrophil or platelet recovery by We did not observe significant differences in neutrophil or platelet recovery between busulfan-containing regimens, BEAC, or ICE. Additional evaluation of the effect of TBI-or busulfan-containing preparative regimens on neutrophil or platelet engraftment kinetics are necessary to determine whether damage to the stromal microenvironment from TB1 or busulfan effects the kinetics of engraftment or whether reported differences reflect small numbers of patients receiving variable numbers of stem cells contained in the PBPC infusion. However, in this analysis, patients receiving CTCb experienced more rapid platelet recovery than did patients receiving busulfan-containing or other HDC preparative regimens. Possible explanations for the more rapid platelet recovery in patients receiving CTCb are that CTCb is not truly myeloablative or is associated with less microenvironment damage than the other regimens evaluated. The optimal use of growth factors after PBPC infusion is currently not defined. The administration of rhG-CSF18s34,40 and rhGM-CSF" has been evaluated in patients receiving PBPCs alone after HDC. Generally, patients receiving a myeloid growth factor have experienced a reduction of 3 to 6 days in the time required to achieve an ANC greater than 0.5 X 109/L but no improvement in the time to platelet recovery. Our analysis supports the observation that administration of a myeloid growth factor after PBPC infusion accelerates neutrophil but not platelet engraftment. Some investigators have reported a trend toward slower platelet recovery in patients receiving a myeloid growth factor after myeloablative therapy and suggested a steal phenomenon whereby hematopoietic progenitors are directed toward myeloid over platelet progenitors preferentially." Our univariate analysis showed a significant delay in platelet recovery in patients receiving a myeloid growth factor that was not observed in multivariate analysis, suggesting that this could be a more predominant phenomenon at lower CD34' cell doses.
These data suggest that the CD34+ cell content of a PBPC collection is a powerful predictor of neutrophil and platelet engraftment kinetics after the administration of myeloablative therapy. A dose-response relationship between the number of CD34+ cells infused and the rate of neutrophil and platelet recovery after myeloablative therapy can be defined; this dose-response relationship can be exploited to define an optimal number of CD34 cells to be infused after HDC. Our data suggest that greater than 5.0 X lo6 CD34+ cellskg is an optimal number of stem cells to ensure rapid hematologic recovery after the administration of myeloablative chemotherapy. Because CD34 enumeration is a powerful surrogate marker for predicting engraftment kinetics, it may also be useful for comparing various techniques of PBPC mobilization. It may be argued that, because both committed and uncommitted progenitor cells express the CD34 antigen, a reliance on CD34 expression will overestimate the true stem cell content of a PBPC collection. It is true that further refinements in stem cell measurement are possible, have biologic significance, and may ultimately have clinical significance regarding applications such as gene therapy. It is currently unknown whether additional refinements in stem cell 63:209, 1986 38. Brice P, Marolleau JP, Dombret H, Leapage E, Baruchel A, Adam M, Micleas JM, Sitthy X, Gisselbrecht C: Autologous peripheral blood stem cell transplantation after high-dose therapy in patients with advanced lymphomas. Bone Marrow Transplant 9:337, 1992 39. Reiffers J, Faberes C, Boiron JM, Marit G , Foures C, Ferrer AM, Cony-Makhoul P, Puntous M, Bernard P, Vezon G, Broustet A: Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: Analysis of factors affecting the rate of engraftment. J Hematother 3:185, 1994 40. Schwartzberg L, Birch R, Weaver C, West W: The effect of varying durations of granulocyte-colony stimulating factor (G-CSF) on neutrophil engraftment and supportive care following peripheral blood progenitor cell (PBPC) infusion. Blood 84:91a, 1994 (abstr, SUPPI 1) For personal use only. on October 27, 2017. by guest www.bloodjournal.org From
